Abstract: An adapter system for facilitating collection of colostrum from a breast may include an adapter, a removable reservoir and a hand-expression funnel. The adapter may include a first open end for connecting to a breast shield of a breast pump system, a second open end for connecting to a breast pump connector of the breast pump system, and a third open end, disposed between the first and second open ends. The removable reservoir may include a wide end for removably attaching to the third open end and a narrow end for attaching to a colostrum delivery device. The hand-expression funnel may include a wide end for receiving colostrum and a narrow end for attaching to the colostrum delivery device. In some embodiments, the colostrum delivery device is a syringe.

Abstract: A solution is proposed for dispensing substances to be taken by a user. A corresponding dispensing device comprises a memory for storing an indication of a taking plan of a plurality of doses of one or more substances, the taking plan comprising an indication of a taking time of each dose, a plurality of compartments each one for containing one of the doses, a signaling unit for providing a taking notice of each dose in response to the corresponding taking time, a pushbutton for releasing the dose corresponding to each taking notice from the corresponding compartment in response to a releasing command; the dispensing device comprises a plate having a collecting surface in a central zone thereof, the compartments being arranged in a peripheral zone of the plate and the pushbutton facing towards the central zone of the plate for collecting the doses released thereby onto the collecting surface.

Abstract: A method for reducing drug administration errors is provided. The method may include manufacturing a drug with a specified color indicator. The method may include receiving an instruction to dispense a desired medication and dosage. The method may include loading a drug into a dispensing device. The method may include initiating a color spectroscopy sequence. The method may include determining, using color spectroscopy, the class of the loaded drug. The method may include determining whether the class of the loaded drug matches the class of the desired medication and dosage.

Abstract: An automatic medication dispenser device includes a container structure for containing medications (pills or liquids). There is a display screen on the container displaying the current date and time, name of patient (user), prescription name and dosage, when the prior dose was taken and when the next one is due. A button is push to activate the dispensing of the medication. The provider can control the AMD remotely: proper use of the medication and interact through video (telemedicine) with the patient. Only a provider such as (doctor, nurses or pharmacist) will be able to access the area where medicines are contained since it requires a special key.

Abstract: An enteral feeding connector facilitates an increased flow rate into and through the connector to accommodate feeding fluids requiring higher flow rates for delivery. The connector includes a male connector portion including an inlet, a fluid passage in fluid communication with the inlet, and at least one connector projection at the inlet. The connector projection defines a cross-sectional area of the inlet configured to facilitate delivering feeding fluid requiring higher flow rates through the connector.

Abstract: A pacifier for dispensing a liquid such as milk, the pacifier including a nipple, including a milk entering aperture disposed at a first end of the nipple, a milk expelling aperture disposed at a second end of the nipple opposite from the first end of the nipple, and a milk holding portion to hold milk therein and to receive the nipple, the milk receiving portion including a milk supplying aperture to correspond to the milk entering aperture of the nipple to supply milk from the milk holding portion to the nipple.

Abstract: A pacifier and teether assembly is disclosed. In one embodiment, the pacifier and teether assembly comprises a nipple, a shield and a teether manufactured as a one-piece assembly comprising a single molded piece of material. In one example embodiment, the nipple and teether are each contiguous to the shield, wherein the shield has a first face opposite a second face. The nipple extends from the first face of the shield. The teether extends from the second face of the shield. In one example embodiment, the pacifier and teething ring assembly is made of 100% medical grade silicone. Such 100% medical grade silicone is free of BPA, PVC, phthalates and latex. A method for using a pacifier and teether assembly is also disclosed.

Abstract: To provide a composite for a dental pattern resin whose shrinkage when curing and expansion when heated can be both suppressed as its usability is kept, the composite for a dental pattern resin includes a liquid formulation and a powder formulation, wherein the liquid formulation includes a polymerizable monofunctional (meth)acrylate, a polymerizable polyfunctional (meth)acrylate, and a polymerization accelerator, and the powder formulation includes more than 5 mass % of a (meth)acrylate copolymer on the basis of the total powder formulation.

Abstract: Provided is a powder formulation for a dental composite which prevents aggregation, makes it easy to be obtained by a proper amount, and makes it possible to suppress formation of incineration residues after mixed with a liquid formulation for a dental composite to form resin. The powder formulation includes a flowability-improving agent in the form of powder, the flowability-improving agent being comprising polymethyl (meth)acrylate, the flowability-improving agent having a volume median particle diameter of 0.02 ?m to 50 ?m.

Abstract: A fibrous structure with a plurality of fibrous elements and agglomerated particles. The agglomerated particles can be matrix particles containing perfume.

Abstract: Matrix particles containing one or more matrix materials and one or more hydrophobic active agents, agglomerated particles made therefrom, fibrous structures containing such matrix particles and/or agglomerated particles, and processes for making same are provided.

Abstract: An oil-in-water emulsion composition includes component (A): from 0.1 to 5% by mass of a hydrophilic nonionic surfactant, component (B): more than 0.02% by mass to less than 0.5% by mass of an anionic surfactant, component (C): from 0.5 to 6% by mass of a higher alcohol, and component (D): from 2 to 30 mmol/100 g of an organic acid and/or a salt and/or derivative thereof. The component (A) includes a polyoxyalkylene alkyl ether and/or a polyalkylene glycol fatty acid ester.

Abstract: Disclosed is a method for improving the sensorial and/or aesthetic properties of an oil-in-water type emulsion for topical application, the method including an effective quantity of a mixture of saturated cyclic or acyclic, linear or branched hydrocarbons of which at least 95% by weight have between fifteen and nineteen carbon atoms. Also disclosed is a new sun-cream emulsion and the use of same to protect the skin.

Abstract: A microcapsule system may include an outer microcapsule having an outer capsule shell where the outer microcapsule comprises at least one inner microcapsule with an inner capsule shell and a first fragrance composition. The inner microcapsule may include a second fragrance composition that differs from the first fragrance composition. Methods for the production thereof, products that contain said microcapsules, methods for producing polysensory olfactory impressions, and to the corresponding use of the microcapsule system, are also disclosed.

Abstract: Certain alkaline dentifrice compositions with relatively high level of water and calcium-containing abrasive, a bicarbonate salt, are effective in treating dental plaque biofilm.

Abstract: A method for the anti-ageing cosmetic treatment of the skin or of the hair applying a hydrocarbon oil that has a content by weight of isoparaffins ranging from 90 to 100%, a content by weight of normal paraffins ranging from 0 to 10% and a content of carbon of biological origin greater than or equal to 90% relative to the total weight of the hydrocarbon oil.

Abstract: The present disclosure relates to a makeup removing composition comprising: (a) about 5 to about 50 wt. % of exfoliating particles; (b) about 5 to about 30 wt. % of glycerin; (c) about 1 to about 50 wt. % of one or more natural fatty compounds; and (d) about 25 to about 75 wt. % of one or more nonionic surfactants; wherein the weight percentages are based on the total weight of the composition. In addition to effectively removing makeup, the composition both exfoliates and hydrates the skin. Accordingly, the disclosed includes method for removing makeup from the skin and/or methods for exfoliating and hydrating the skin.

Abstract: Cosmetic preparation containing a) one or more alkane diols selected from the group of the compounds propylene glycol, butylene glycol, 2-methylpropane-1,3-diol, ethylhexylglycerol, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and/or 1,2-decanediol, and b) sodium chloride in a concentration of 0.25 to 5% by weight, based on the total weight of the preparation.

Abstract: Hair treatment agents, including at least one fatty alcohol, at least one cationic surfactant, at least one bivalent or trivalent metal salt, at least one amino-functional silicone, propionic acid and/or salts of propionic acid, and at least one of organic acid different from propionic acid, reduce or prevent the washing out of color from dyed hair.

Abstract: Pyruvate may be used to stabilize hyaluronic acid compositions. For example, these compositions may have improved heat and/or storage stability.

Abstract: A composition provides a protective barrier and includes glyceryl dibehenate, tribehenin, and glyceryl behenate, a surfactant that includes glyceryl stearate, hydrogenated vegetable oil, one or more additional fatty compounds, and one or more triglyceride. The composition optionally includes wax, a hydrating agent, and may be essentially free of or is devoid of one or more of petrolatum, mineral oil and water. The composition provides occlusivity and hydration effects that are comparable to compositions that include one or more of petrolatum, mineral oil and lanolin.

Abstract: A composition provides a protective barrier and includes glyceryl dibehenate, tribehenin, and glyceryl behenate, a surfactant that includes glyceryl stearate, one or more fatty compounds, and one or more triglyceride. The composition optionally includes a hydrating agent and may be essentially free of or is devoid of one or more of petrolatum, mineral oil and water. The composition provides occlusivity and hydration effects that are comparable to compositions that include one or more of petrolatum, mineral oil and lanolin.

Abstract: The subject of the invention is a wax-in-water emulsion containing at least one fatty acid ester of tetramethylpropylethylenediamine, which is intended to replace triethanolamine, known to decompose into nitrosamines when the preserved emulsion is packaged in a thermoplastic material. Moreover, this emulsion has the advantage of gaining shade depth and fluidity, especially in products rich in waxes.

Abstract: The invention relates to a composition in the form of an oil-in-water emulsion, in particular a cosmetic and/or dermatological composition, comprising in a physiologically acceptable aqueous medium: a) at least Baicalin and/or one of the derivatives thereof or a plant extract containing it, b) at least one superabsorbent polymer, c) at least one homo- or copolymer of non-superabsorbent acrylic acid that is at least partially neutralized, and d) at least one gemini surfactant with formula (III), said composition having a p H of 6.0 to 6.5. The invention also relates to a cosmetic care and/or makeup method for keratin materials, comprising the topical application of a composition according to the invention on keratin materials.

Abstract: The invention relates to a concentrate comprising at least one mannosylerythritol lipid and at least one polyglycerol and fatty acid ester, to a method for the production thereof, and to the uses of same, particularly as a thickening, foaming and/or cleaning agent.

Abstract: A compound additive having a biological activation function. The compound additive contains water or phosphate buffer, and multiple proteins and various factors dissolved therein. The compound additive can be added into a culture medium for cell cultivation, and can also be directly used or added into a skin repair product or a cosmetic product so as to achieve certain skin repair and cosmetic effects.

Abstract: The present invention discloses preservative-free toothpaste for children. The composition forming the preservative-free toothpaste for children consists of vitamin, calcium glycerophosphate, xylitol, sorbitol, polyethylene glycol, cellulose, hydroxypropyl guar gum, sodium lauryl sulfate, flavors and deionized water. The composition contains, by weight percentage, 0.01-0.06% of vitamin, 0.1-0.5% calcium glycerophosphate and 0.1-1% of xylitol. The vitamin comprises both vitamin E and vitamin C. In the present invention, vitamin E, vitamin C, calcium glycerophosphate and xylitol are combined in a certain proportion. The vitamin nourishes the children's tender gums. The calcium glycerophosphate provides calcium supplementation to the teeth. The xylitol has a reduced content of sugar, which prevents tooth decay and strengthens the teeth.

Abstract: This invention provides for a gel texturizer base for cosmetic products. The bases are excipients that provide a gel-like texture to cosmetic products. The gel texturizer bases of this invention are from non-petroleum based products and comprise over 85% juice derived solvent with the balance being a combination of a texture enhancer and a gum texture modifier.

Abstract: The present invention relates to an anhydrous solid composition for dyeing keratin fibres, in particular human keratin fibres such as the hair, comprising a particular chemical oxidizing agent and a polymer comprising at least one heterocyclic vinyl monomer. The present invention also relates to a packaging article containing said composition. The present invention also relates to processes for dyeing keratin fibres using said composition or said packaging article. Finally, the present invention relates to the use of said composition or of said packaging article for dyeing keratin fibres, and in particular human keratin fibres such as the hair.

Abstract: The instant disclosure generally relates to a dual component hair coloring composition for coloring mammalian or synthetic keratin fibers, the composition comprising composition A comprising a cationic polymer, pigment microparticles and an aqueous medium, and comprising composition B comprising an anionic polymer, aqueous medium and optional cross linking agent. Optionally or alternatively composition B may contain pigment particles. The cationic and anionic polymers are at least partially soluble in the medium and the pigment microparticles are dispersed therein. The hair coloring composition forms a dual layer coating upon application to keratin fibers such as hair and has a substantially permanent pigment lastingness following development (setting); minimally alters the keratin fibers, upon application; and substantially eliminates development time. Methods of using such compositions are also described herein.

Abstract: The present invention relates to a cosmetic process for treating keratin fibres, preferably human keratin fibres such as the hair, in particular for conditioning keratin fibres, using a combination of at least two different compositions, the first composition comprising one or more oxyalkylenated and preferably oxyethylenated silicones and one or more cationic surfactants and the second composition comprising water and one or more amino silicones. The invention also relates to a kit comprising the two compositions. Finally, the invention relates to a ready-to-use cosmetic composition for treating keratin fibres.

Abstract: The present invention provides a facial mask composition, comprising by weight percentage, the following ingredients: (a) 0.01% to 30% of emollient oil; (b) 0.01% to 20% of moisturizer; (c) 0.01% to 10% of thickening polymer; (d) 0.01% to 10% of skin conditioner; and (e) 10% to 90% of deionized water; wherein, the skin conditioner comprises, by weight parts: Radix Astragali 20, Aloe vera 30, Radix Angelicae Dahuricae 20 and Poria cocos 30.

Abstract: The present disclosure provides methods and compositions for the treatment of oral lesions in a subject comprising a methylene blue oral rinse.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: The invention relates to an extruded depot form for a continuing active substance release, comprising at least one active substance and at least two compounds of the class of substances which can be broken down by lipases. The at least two compounds comprise a low-melting compound and a high-melting compound, and the ratio of the low-melting compound to the high-melting compound ranges from 1:9 to 9:1. The depot form also optionally comprises at least one auxiliary agent for modulating the active substance release, wherein b), or optionally b) and c), constitute at least 60 wt. % of the dry weight of the depot form.

Abstract: The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.

Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.

Abstract: The invention pertains to methods of manufacturing soft chews containing highly heat-labile and moisture-labile active agents. The invention pertains to methods for manufacturing soft chew, comprising a) heating at a non-aqueous liquid carrier to a temperature of at least about 50° C., b) mixing the heated non-aqueous liquid carrier with at least one binding agent to form a uniform solution, c) mixing a solid excipient with the mixture produced in step b) to form a smooth dough, d) cooling the dough to about 30° C., e) mixing an active agent with the cooled dough, and f) forming soft chews from the dough produced in step e). The invention also pertains to soft chews manufactured by the methods of the invention. The soft chews produced according to these methods exhibit surprisingly higher stability of moisture-labile active agents while still providing desirable soft chew properties, such as soft moisture texture, taste, and palatability.

Abstract: An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.

Abstract: The present application relates to compositions for the release of carbon dioxide following rectal administration comprising acid plant juices supported on gum and at least a salt of carbonic acid. Such compositions resulted to be particularly effective in stimulating evacuation, in particular showed an optimum kinetics of carbon dioxide release.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Abstract: A polymer construct includes at least one extruded degradable polymer layer having a host polymer material and at least one amphiphilic star-shaped polymer miscible with the host polymer material. The star-shaped polymer includes a polymer core and polymer branches extending therefrom to define a shell around the core. A guest agent is loaded on and/or within the core. The polymer construct upon delivery to a site of interest provides controlled and/or sustained release of the guest agent upon degradation of the at least one polymer layer.

Abstract: Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.

Abstract: The invention provides a method of preparing a lyophilized pharmaceutical composition containing a compound described herein or a pharmaceutically-acceptable salt thereof. The process comprises dissolving the compound in a solvent comprising dimethylsulfoxide and optionally one or more co-solvents to form a solution, and then removing the solvent and any co-solvents by a freeze-drying process. Also provided by the invention are lyophilized pharmaceutical compositions and their use in medicine and in particular in the treatment of cancer.

Abstract: Capsule dosage forms that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the dosage forms comprise at least one pharmaceutically active ingredient, a combination of hydrophilic gelling polymers, at least one organic acid, and at least one disintegrant.

Abstract: Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.